The Rules of T-cell Engagement: Current State of CAR T-cells and Bispecific Antibodies in B-cell Lymphomas.
Julie Erika HayduJeremy S AbramsonPublished in: Blood advances (2024)
T-cell engaging-therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on advances in chimeric antigen receptor modified T-cells (CAR T-cells) and bispecific antibodies (BsAb), first providing an overview of each product type, followed by exploring the primary data for currently available products in large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. This review also highlights key logistical and sequencing considerations across diseases and product types that can impact clinical decision making.
Keyphrases
- decision making
- diffuse large b cell lymphoma
- hodgkin lymphoma
- induced apoptosis
- single cell
- acute myeloid leukemia
- acute lymphoblastic leukemia
- cell cycle arrest
- social media
- multiple myeloma
- electronic health record
- machine learning
- cell death
- combination therapy
- endoplasmic reticulum stress
- deep learning
- data analysis